We’ve been able to take exactly that same motif, exactly that same protein structure into the laboratory and build out a library of proteins that allow us to target with singular specificity any endogenous gene. And so this is our core technology. And we can use this to drive biologies from the DNA, at the DNA level. And it’s that opportunity which really differentiates us and defines our strategy and business model going forward.So our internal focus is to employ this technology in the area of human therapeutics, but we’ve also been quite successful in leveraging this into areas outside of human therapeutics in partnerships in the area of life science research, as well as in plant agriculture. And I’ll cover those at the end of the presentation.
Sangamo BioSciences' CEO Presents At The 2012 Wedbush PacGrow Lifesciences Management Access Conference (Transcript)
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts